…
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Veracyte is a genomics diagnostics company that develops and commercializes tests to improve diagnosis and treatment decisions in oncology and other areas, notably thyroid, lung and prostate disease. Long-term growth may be supported by wider clinical adoption of its existing test portfolio, international expansion, and stronger guideline and payer acceptance. The company appears positioned to translate clinical validation into recurring, service-based revenue as physicians integrate molecular diagnostics into care pathways.
Key investment risks include reimbursement and regulatory uncertainty, competition from other molecular and in-house tests, and execution risk in scaling commercial operations and reaching sustained profitability.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | 68.20M | 25.74M | -76.61M | -36.43M | -81.65M |
| Net income | 66.35M | 24.14M | -74.40M | -36.56M | -75.56M |
| Selling general administrative | 110.78M | 178.27M | 157.63M | 76.52M | 101.35M |
| Selling and marketing expenses | 100.17M | 27.77M | 26.60M | 97.56M | 79.84M |
| Gross profit | 360.05M | 298.14M | 248.15M | 194.95M | 145.11M |
| Reconciled depreciation | 21.41M | 23.46M | 27.41M | 25.93M | 19.59M |
| Ebit | 68.20M | 25.75M | -76.60M | -41.08M | -81.90M |
| Ebitda | 89.62M | 49.20M | -49.41M | -15.15M | -62.31M |
| Depreciation and amortization | 21.41M | 23.46M | 27.19M | 25.93M | 19.59M |
| Non operating income net other | - | - | - | 4.65M | 0.25M |
| Operating income | 74.15M | 16.14M | -85.80M | -41.08M | -81.90M |
| Other operating expenses | 443.00M | 429.62M | 446.85M | 337.62M | 301.42M |
| Interest expense | 0.00M | 0.00M | 0.01M | -4.65M | 0.24M |
| Tax provision | 1.85M | 1.61M | 0.37M | 0.13M | -6.09M |
| Interest income | 12.72M | 11.15M | 5.67M | 1.97M | 0.14M |
| Net interest income | 12.72M | 11.15M | 5.65M | 1.77M | -0.11M |
| Income tax expense | 1.85M | 1.61M | -2.21M | 0.13M | -6.09M |
| Total revenue | 517.14M | 445.76M | 361.05M | 296.54M | 219.51M |
| Total operating expenses | 285.89M | 282.00M | 333.94M | 236.03M | 227.02M |
| Cost of revenue | 157.10M | 147.62M | 112.90M | 101.58M | 74.40M |
| Total other income expense net | -5.95M | 9.60M | 9.18M | 4.65M | 0.25M |
| Net income from continuing ops | 66.35M | 24.14M | -49.95M | -36.56M | -75.56M |
| Net income applicable to common shares | - | - | - | -36.56M | -75.56M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 1406.02M | 1300.04M | 1137.82M | 1156.42M | 1187.83M |
| Intangible assets | 89.15M | 102.30M | 88.59M | 174.87M | 202.73M |
| Other current assets | 10.28M | 14.55M | 7.96M | 11.47M | 17.22M |
| Total liab | 96.44M | 124.07M | 93.72M | 81.22M | 91.31M |
| Total stockholder equity | 1309.58M | 1175.97M | 1044.10M | 1075.20M | 1096.51M |
| Deferred long term liab | - | - | - | 4.53M | 5.59M |
| Other current liab | 50.13M | 60.83M | 41.19M | 44.02M | 42.39M |
| Common stock | 0.08M | 0.08M | 0.07M | 0.07M | 0.07M |
| Capital stock | 0.08M | 0.08M | 0.07M | 0.07M | 0.07M |
| Retained earnings | -377.63M | -443.98M | -468.12M | -393.72M | -357.16M |
| Other liab | - | - | - | 7.56M | 13.06M |
| Good will | 767.15M | 745.80M | 702.98M | 695.89M | 707.90M |
| Other assets | - | -33.98M | 0.00M | 6.17M | 2.95M |
| Cash | 362.58M | 239.09M | 216.45M | 154.25M | 173.20M |
| Total current liabilities | 59.94M | 78.63M | 61.24M | 62.61M | 64.15M |
| Current deferred revenue | 1.16M | 1.67M | 2.01M | 2.61M | 4.65M |
| Net debt | -322.92M | -188.35M | -203.82M | -139.53M | -154.34M |
| Short term debt | 4.05M | 7.50M | 5.11M | 4.07M | 4.76M |
| Short long term debt | - | - | - | - | 1.13M |
| Short long term debt total | 39.65M | 50.74M | 12.63M | 14.72M | 18.85M |
| Other stockholder equity | 1695.34M | 1655.96M | 1536.17M | 1500.19M | 1468.68M |
| Property plant equipment | - | - | - | 30.86M | 31.14M |
| Total current assets | 488.38M | 372.27M | 285.62M | 248.64M | 243.10M |
| Net tangible assets | - | - | - | 379.31M | 185.88M |
| Short term investments | 50.31M | 50.35M | 0.00M | 24.61M | - |
| Net receivables | 44.66M | 46.52M | 45.08M | 44.02M | 41.46M |
| Inventory | 20.55M | 21.75M | 16.13M | 14.29M | 11.22M |
| Accounts payable | 4.59M | 8.63M | 12.94M | 11.91M | 12.36M |
| Accumulated other comprehensive income | -8.21M | -36.09M | -24.02M | -31.35M | -15.08M |
| Common stock total equity | - | - | - | 0.07M | 0.07M |
| Retained earnings total equity | - | - | - | -393.72M | -357.16M |
| Non currrent assets other | 2.55M | 8.53M | 5.97M | 6.17M | 2.95M |
| Non current assets total | 917.64M | 927.77M | 852.20M | 907.79M | 944.72M |
| Capital lease obligations | 39.65M | 50.74M | 12.63M | 14.72M | 17.73M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 3.31M | -56.27M | -8.82M | -20.84M | 3.00M |
| Change to liabilities | - | - | - | 0.15M | 5.16M |
| Total cashflows from investing activities | -9.21M | -56.27M | 15.11M | -29.39M | -739.21M |
| Net borrowings | - | 0.00M | 0.00M | -1.28M | -1.28M |
| Total cash from financing activities | -4.22M | 4.90M | 2.84M | 3.49M | 596.32M |
| Change to operating activities | - | - | - | -9.03M | 9.10M |
| Net income | 66.35M | 24.14M | -74.40M | -36.56M | -75.56M |
| Change in cash | 123.59M | 23.30M | 62.33M | -18.95M | -176.02M |
| Begin period cash flow | 240.63M | 217.33M | 155.00M | 173.95M | 349.97M |
| End period cash flow | 364.23M | 240.63M | 217.33M | 155.00M | 173.95M |
| Total cash from operating activities | 136.31M | 75.10M | 44.22M | 7.54M | -31.62M |
| Issuance of capital stock | - | - | 0.00M | 0.00M | 593.82M |
| Depreciation | 21.41M | 23.46M | 27.19M | 25.93M | 19.59M |
| Other cashflows from investing activities | -2.85M | - | - | - | -736.83M |
| Change to inventory | -2.86M | -5.87M | -1.69M | -3.01M | -1.46M |
| Change to account receivables | -0.71M | -6.41M | 3.89M | 1.10M | -8.57M |
| Sale purchase of stock | - | - | -6.74M | 7.94M | 11.53M |
| Other cashflows from financing activities | -18.30M | -15.09M | 2.84M | -3.17M | 2.50M |
| Change to netincome | - | - | - | 27.62M | 26.39M |
| Capital expenditures | 9.68M | 11.29M | 9.96M | 8.55M | 5.38M |
| Change receivables | - | - | - | -4.50M | -8.57M |
| Cash flows other operating | - | - | - | -2.10M | 4.69M |
| Cash and cash equivalents changes | - | - | - | -18.36M | -174.51M |
| Change in working capital | -2.30M | -20.96M | -3.69M | -16.38M | 4.22M |
| Stock based compensation | 43.60M | 36.25M | 33.14M | 26.73M | 22.52M |
| Other non cash items | 7.82M | 12.45M | 65.83M | 7.68M | 3.87M |
| Free cash flow | 126.63M | 63.81M | 34.26M | -1.01M | -37.00M |
Sector: Healthcare Industry: Diagnostics & Research
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| VCYT Veracyte Inc |
-0.30 1.22% |
24.33 | 28.67 | 22.12 | 5.74 | 2.38 | 5.10 | 20.94 |
| TMO Thermo Fisher Scientific Inc |
0.78 0.11% |
700.22 | 34.71 | 23.87 | 4.62 | 4.43 | 5.29 | 20.89 |
| DHR Danaher Corporation |
0.86 0.37% |
233.02 | 29.09 | 28.01 | 5.67 | 3.20 | 6.00 | 19.09 |
| WUXIF WuXi AppTec Co. Ltd |
-0.28 1.14% |
24.63 | 22.29 | 17.95 | 1.53 | 5.98 | 8.39 | 14.30 |
| WUXAY WuXi AppTec Co. Ltd |
-1.12 4.41% |
24.28 | 23.28 | 18.73 | 1.51 | 6.24 | 8.39 | 14.30 |
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
6000 Shoreline Court, South San Francisco, CA, United States, 94080
650 243 6300
755
| Name | Title | Year Born |
|---|---|---|
| Ms. Bonnie H. Anderson | Co-Founder & Exec. Chairwoman | 1958 |
| Mr. Marc A. Stapley | CEO & Director | 1970 |
| Ms. Rebecca Chambers | Exec. VP & CFO | 1978 |
| Dr. Giulia C. Kennedy Ph.D. | Global Chief Scientific Officer & Chief Medical Officer | 1959 |
| Dr. Tina S. Nova Ph.D. | Pres of CLIA U.S. Bus. | 1954 |
| Ms. Beverly Jane Alley CPA | VP & Corp. Controller | 1963 |
| Mr. Jonathan Wygant | VP & Chief Accounting Officer | 1971 |
| Mr. Steven French | Sr. VP & Chief Information Officer | NA |
| Ms. Annie McGuire | Sr. VP & Gen. Counsel | 1980 |
| Ms. Tracy Morris | VP of Global Corp. Communications | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.